EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

RGD peptide in cancer targeting: Benefits, challenges, solutions, and possible integrin–RGD interactions

Hossein Javid iD, Mahsa Akbari Oryani, Nastaran Rezagholinejad, Ali Esparham, Mahboubeh Tajaldini, Mehdi Karimi-Shahri iD

Cancer Medicine · 2024-01 · 13 (2)

DOI: 10.1002/cam4.6800 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Medicine, 2024-02. Verfasst von Hossein Javid und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Laboratory Sciences, Varastegan Institute for Medical Sciences, Mashhad, Iran. Hauptthemen laut MEDLINE: Oligopeptides, Neoplasms. Die Arbeit wurde bisher 298-mal zitiert (Crossref) und nennt 268 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RGD peptide can be found in cell adhesion and signaling proteins, such as fibronectin, vitronectin, and fibrinogen. RGD peptides' principal function is to facilitate cell adhesion by interacting with integrin receptors on the cell surface. They have been intensively researched for use in biotechnology and medicine, including incorporation into biomaterials, conjugation to medicinal molecules or nanoparticles, and labeling with imaging agents. RGD peptides can be utilized to specifically target cancer cells and the tumor vasculature by engaging with these integrins, improving drug delivery efficiency and minimizing adverse effects on healthy tissues. RGD‐functionalized drug carriers are a viable option for cancer therapy as this focused approach has demonstrated promise in the future. Writing a review on the RGD peptide can significantly influence how drugs are developed in the future by improving our understanding of the peptide, finding knowledge gaps, fostering innovation, and making drug design easier.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OligopeptidesNeoplasmsHumansPeptidesIntegrins

Stichwörter der Autor:innen

RGD peptidescancer targetingchallengesconjugation process

Substanzen

arginyl-glycyl-aspartic acidOligopeptidesPeptidesIntegrins

Autor:innen und Institutionen

  • Department of Medical Laboratory Sciences, Varastegan Institute for Medical Sciences, Mashhad, Iran.
  • Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Department of Pathology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Department of Biochemistry, Payame Noor University (PNU), Mashhad, Iran.
  • Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

ORCID-Profile: Hossein Javid, Mehdi Karimi-Shahri

Zitieren

APA

Javid, H., Oryani, M. A., Rezagholinejad, N., Esparham, A., Tajaldini, M., & Karimi-Shahri, M. (2024). RGD peptide in cancer targeting: Benefits, challenges, solutions, and possible integrin–RGD interactions. Cancer Medicine, 13(2). https://doi.org/10.1002/cam4.6800

Vancouver

Javid H, Oryani MA, Rezagholinejad N, Esparham A, Tajaldini M, Karimi-Shahri M. RGD peptide in cancer targeting: Benefits, challenges, solutions, and possible integrin–RGD interactions. Cancer Medicine. 2024;13(2). doi:10.1002/cam4.6800

BibTeX
@article{Javid2024,
  author = {Javid, Hossein and Oryani, Mahsa Akbari and Rezagholinejad, Nastaran and Esparham, Ali and Tajaldini, Mahboubeh and Karimi-Shahri, Mehdi},
  title = {RGD peptide in cancer targeting: Benefits, challenges, solutions, and possible integrin–RGD interactions},
  journal = {Cancer Medicine},
  year = {2024},
  volume = {13},
  number = {2},
  doi = {10.1002/cam4.6800}
}
Kostenlos starten →